Information Provided By:
Fly News Breaks for May 29, 2019
URGN
May 29, 2019 | 06:11 EDT
Goldman Sachs analyst Paul Choi started UroGen Pharma with a Neutral rating and $50 price target, which represents 37% upside potential. The analyst sees "relatively low" clinical risk with UroGen's current clinical candidates, but is "somewhat more cautious" on commercial execution as he believes adoption will require training doctors in a new procedure. Choi expects UGN-101 to be approved for treatment of upper tract urothelial carcinoma.
News For URGN From the Last 2 Days
There are no results for your query URGN
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.